Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2020 Mar 24;64(4). pii: e00315-20. doi: 10.1128/AAC.00315-20. Print 2020 Mar 24. No abstract available.

PMID:
32209563
2.

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.

Schutz C, Chirehwa M, Barr D, Ward A, Janssen S, Burton R, Wilkinson RJ, Shey M, Wiesner L, Denti P, McIlleron H, Maartens G, Meintjes G.

Br J Clin Pharmacol. 2020 Jan 7. doi: 10.1111/bcp.14207. [Epub ahead of print]

PMID:
31912537
3.

Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.

Ghafari N, Court R, Chirehwa MT, Wiesner L, Petersen L, Maartens G, Gumbo T, McIlleron H, Ramma L.

Int J Audiol. 2020 Mar;59(3):219-223. doi: 10.1080/14992027.2019.1690170. Epub 2019 Nov 18.

PMID:
31739701
4.

Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis.

Court R, Chirehwa MT, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, McIlleron H.

Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1068-1074. doi: 10.5588/ijtld.18.0775.

PMID:
31627771
5.

Quantitative assessment of the activity of antituberculosis drugs and regimens.

Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H.

Expert Rev Anti Infect Ther. 2019 Jun;17(6):449-457. doi: 10.1080/14787210.2019.1621747. Epub 2019 May 30. Review.

PMID:
31144539
6.

Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02174-18. doi: 10.1128/AAC.02174-18. Print 2019 Jun. Erratum in: Antimicrob Agents Chemother. 2020 Mar 24;64(4):.

7.

Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.

Naidoo A, Chirehwa M, Ramsuran V, McIlleron H, Naidoo K, Yende-Zuma N, Singh R, Ncgapu S, Adamson J, Govender K, Denti P, Padayatchi N.

Pharmacogenomics. 2019 Mar;20(4):225-240. doi: 10.2217/pgs-2018-0166. Epub 2019 Feb 15.

8.

Propagation of measurement errors in glomerular filtration rate determination: a comparison of slope-intercept, single-sample and slope-only methods.

Holness JL, Fleming JS, Chirehwa MT, Warwick JM.

Nucl Med Commun. 2019 Apr;40(4):333-342. doi: 10.1097/MNM.0000000000000977.

PMID:
30664600
9.

Adverse Drug Reactions in Paediatric In-Patients in a South African Tertiary Hospital.

Makiwane M, Decloedt E, Chirehwa M, Rosenkranz B, Kruger M.

J Trop Pediatr. 2019 Aug 1;65(4):389-396. doi: 10.1093/tropej/fmy067.

PMID:
30544245
10.

Current research toward optimizing dosing of first-line antituberculosis treatment.

McIlleron H, Chirehwa MT.

Expert Rev Anti Infect Ther. 2019 Jan;17(1):27-38. doi: 10.1080/14787210.2019.1555031. Epub 2018 Dec 12. Review.

11.

Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Chirehwa MT, McIlleron H, Wiesner L, Affolabi D, Bah-Sow O, Merle C, Denti P; RAFA team.

J Antimicrob Chemother. 2019 Jan 1;74(1):139-148. doi: 10.1093/jac/dky378.

12.

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis.

Court RG, Wiesner L, Chirehwa MT, Stewart A, de Vries N, Harding J, Gumbo T, McIlleron H, Maartens G.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):926-930. doi: 10.5588/ijtld.18.0091.

13.

Assessment of quality of obstetric care in Zimbabwe using the standard primipara.

Guzha BT, Magwali TL, Mateveke B, Chirehwa M, Nyandoro G, Munjanja SP.

BMC Pregnancy Childbirth. 2018 Jun 4;18(1):205. doi: 10.1186/s12884-018-1863-5.

14.

Quality of pilot trial abstracts in heart failure is suboptimal: a systematic survey.

Isiguzo GC, Zunza M, Chirehwa M, Mayosi BM, Thabane L.

Pilot Feasibility Stud. 2018 May 31;4:107. doi: 10.1186/s40814-018-0302-8. eCollection 2018.

15.

Evaluation of the Effectiveness of Dose Individualization to Achieve Therapeutic Vancomycin Concentrations.

Abulfathi AA, Chirehwa M, Rosenkranz B, Decloedt EH.

J Clin Pharmacol. 2018 Sep;58(9):1134-1139. doi: 10.1002/jcph.1254. Epub 2018 May 10.

PMID:
29746714
16.

Quality of abstracts of pilot trials in heart failure: A protocol for a systematic survey.

Isiguzo G, Zunza M, Chirehwa M, Mayosi BM, Thabane L.

Contemp Clin Trials Commun. 2017 Nov 7;8:258-263. doi: 10.1016/j.conctc.2017.11.004. eCollection 2017 Dec.

17.

Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.

Court R, Chirehwa MT, Wiesner L, Wright B, Smythe W, Kramer N, McIlleron H.

Int J Tuberc Lung Dis. 2018 May 1;22(5):537-543. doi: 10.5588/ijtld.17.0697.

18.

Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.

Naidoo A, Ramsuran V, Chirehwa M, Denti P, McIlleron H, Naidoo K, Yende-Zuma N, Singh R, Ngcapu S, Chaudhry M, Pepper MS, Padayatchi N.

Pharmacogenomics. 2018 Jan;19(1):17-29. doi: 10.2217/pgs-2017-0144. Epub 2017 Dec 6.

19.

Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.

Chirehwa MT, McIlleron H, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, Denti P.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00490-17. doi: 10.1128/AAC.00490-17. Print 2017 Aug.

20.

Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.

Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, Kimba-Phongi E, Adamson J, Govender K, Padayatchi N, Denti P.

J Antimicrob Chemother. 2017 May 1;72(5):1441-1449. doi: 10.1093/jac/dkx004.

21.

Correction: Use of the 'Accountability for Reasonableness' Approach to Improve Fairness in Accessing Dialysis in a Middle-Income Country.

Moosa MR, Maree JD, Chirehwa MT, Benatar SR.

PLoS One. 2016 Dec 9;11(12):e0168017. doi: 10.1371/journal.pone.0168017. eCollection 2016.

22.

Use of the 'Accountability for Reasonableness' Approach to Improve Fairness in Accessing Dialysis in a Middle-Income Country.

Moosa MR, Maree JD, Chirehwa MT, Benatar SR.

PLoS One. 2016 Oct 4;11(10):e0164201. doi: 10.1371/journal.pone.0164201. eCollection 2016. Erratum in: PLoS One. 2016 Dec 9;11(12 ):e0168017.

23.

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.

Rockwood N, Meintjes G, Chirehwa M, Wiesner L, McIlleron H, Wilkinson RJ, Denti P.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6050-9. doi: 10.1128/AAC.00480-16. Print 2016 Oct.

24.

Erratum for Chirehwa et al., Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.

Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H, Denti P.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3262. doi: 10.1128/AAC.00483-16. Print 2016 May. No abstract available.

25.

Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.

Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H, Denti P.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):487-94. doi: 10.1128/AAC.01830-15. Print 2016 Jan. Erratum in: Antimicrob Agents Chemother. 2016 May;60(5):3262.

26.

Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial.

Mupfumi L, Makamure B, Chirehwa M, Sagonda T, Zinyowera S, Mason P, Metcalfe JZ, Mutetwa R.

Open Forum Infect Dis. 2014 Jun 25;1(1):ofu038. doi: 10.1093/ofid/ofu038. eCollection 2014 Mar.

27.

Elective reconstruction of the ascending aorta for aneurysmal disease restores normal life expectancy. An analysis of risk factors for early and late mortality.

Van Duffel D, Van Gemert R, Starinieri P, Pauwels JL, Natukunda A, Rakhmawati TW, Chirehwa MT, Orwa J, Thys H, Deboosere P, Robic B, Mees U, Hendrikx M.

Acta Cardiol. 2013 Aug;68(4):349-53.

PMID:
24187760
28.

Renal abnormalities among HIV-infected, antiretroviral naive children, Harare, Zimbabwe: a cross-sectional study.

Dondo V, Mujuru HA, Nathoo KJ, Chirehwa M, Mufandaedza Z.

BMC Pediatr. 2013 May 11;13:75. doi: 10.1186/1471-2431-13-75.

29.

An assessment of the maternal death notification system in Zimbabwe--2006.

Magwali TL, Mataya R, Munjanja SP, Chirehwa M.

Cent Afr J Med. 2011 Jan-Apr;57(1-4):8-11.

PMID:
24968656
30.

Consequences of polyparasitism on anaemia among primary school children in Zimbabwe.

Midzi N, Mtapuri-Zinyowera S, Mapingure MP, Sangweme D, Chirehwa MT, Brouwer KC, Mudzori J, Hlerema G, Mutapi F, Kumar N, Mduluza T.

Acta Trop. 2010 Jul-Aug;115(1-2):103-11. doi: 10.1016/j.actatropica.2010.02.010. Epub 2010 Feb 20.

PMID:
20175980

Supplemental Content

Loading ...
Support Center